DC
LENZ

Diametric Capital’s LENZ Therapeutics LENZ Stock Holding History

Diametric Capital’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-5,186
Closed -$94.4K – 448
2023
Q2 		$94.4K Buy
+5,186
New +$104K 0.04% 282

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Diametric Capital's LENZ Position: Q3 2023 in Review

Diametric Capital sold out of LENZ Therapeutics (LENZ) in Q3 2023, closing a stake of 5,186 shares — an estimated $94.4K sold.

Diametric Capital first reported a position in LENZ in Q2 2023 and held it in 1 quarter. The position peaked at $94.4K in Q2 2023. 67 funds tracked by Wall St. Rank hold LENZ as of Q3 2023.

  • Diametric Capital reported no remaining LENZ Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Diametric Capital sold 5,186 LENZ Therapeutics shares in Q3 2023, an estimated $94.4K.
  • Diametric Capital first reported a position in LENZ Therapeutics in Q2 2023 and held it in 1 quarter.
  • Diametric Capital's LENZ Therapeutics position peaked at $94.4K in Q2 2023.
  • 67 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q3 2023.

Based on Diametric Capital's 13F filing for Q3 2023, filed 14 Nov 2023.